A risk-benefit assessment of mirtazapine in the treatment of depression

Drug Safety

Volumn 17, Issue 4, 1997, Pages 251-264

  Kasper, Siegfried ^a   Praschak Rieder, Nicole ^a   Tauscher, Johannes ^a   Wolf, Rainer ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450; DOXEPIN; FLUOXETINE; MIRTAZAPINE; SEROTONIN 1 RECEPTOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; APPETITE DISORDER; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 0030724679     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717040-00005     Document Type: Review

References (65)

1. 1A-mediated serotonergic neurotransmission. CNS Drugs 1995; 4 Suppl. 1: 29-38
2. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 11-7
3. de Boer Th. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57 Suppl. 4: 19-26
4. O'Connor WT, Leonard BE. Effect of chronic administration of the 6-aza-analogue of mianserin (Org 3770) and its enantiomers on behaviour and changes in norepinephrine metabolism of olfactory-bulbectomised rats in the 'open-field apparatus. Neuropharmacology 1985; 25: 267-70
5. Ruigt GSF, Engelen S, Gerrits A, et al. Computer based prediction of psychotropic drug classes based on a discriminant analysis of drug effects on rat sleep. Neuropsychobiology 1993; 28: 138-53
6. 2-adrenergic agonist clonidine. Brain Res 1975; 92: 291-306
7. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980; 19: 355-63
8. de Boer T, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin. Org 3770 and its enantiomers. Neuropharmacology 1988; 27: 399-408
9. 2-antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994; 253: R5-6
10. Ruigt GSF, Kemp B, Groenhout CM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990; 38: 551-4
11. Kasper S. Clinical efficacy of mirtazapine: a review of meta- analyses of pooled data. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 25-35
12. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 37-45
13. Cohen M, Panagides J, Timmer CJ, et al. Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Eur J Drug Metab Pharmacokinet 1997; 22: 103-10
14. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tablets. Hum Psychopharmacol 1995; 10 Suppl. 2: S97-106
15. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Hum Psychopharmacol 1995; 10 Suppl. 2: S83-96
16. Delbressine LPC, Vos RME. The clinical relevance of preclinical data. Mirtazapine, a model compound. J Clin Psychopharmacol 1997; 17 Suppl. 1: 29-34
17. Timmer CJ, Paanakker JE, Vrijmoed-de Vries M. Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. Pharm Res 1997; 14: 98-102
18. Timmer CJ, Paanakker JE, van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of age, gender and treatment regimen. Hum Psychopharmacol 1996; 11: 497-509
19. Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in man. Clin Drug Invest 1997; 13: 37-46
20. Mattila M, Mattila MJ, Vrijmoed-de Vries M, et al. Action and interaction of psychotropic drugs on human performance and mood: single doses of Org 3770, amitriptyline and diazepam. Pharmacol Toxicol 1989; 65: 81-8
21. Sitsen JMA. Lack of pharmacokinetic interaction between mirtazapine and lithium [abstract]. Biol Psychiatry 1997; 42: 45S
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987
24. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995; 56: 519-25
25. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995; 34: 165-71
26. Khan MC. A randomised, double-blind, placebo-controlled. 5-weeks study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995; 10 Suppl. 2: S119-24
27. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depression. Psychopharmacol Bull 1990; 26: 191-6
28. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994; 4: 145-50
29. Jacobson AF, Dominguez RA, Goldstein B et al. Comparison of Org 3770 and amitriptyline in depressed outpatients [abstract]. J Clin Pharmacol 1990; 30: 851
30. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995; 10 Suppl. 2: S125-33
31. Mullin J, Lodge A, Bennie E, et al. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with depression. J Psychopharmacol 1996; 10: 235-40
32. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind trial in hospitalized depressed patients. Hum Psychopharmacol 1995; 10: 173-80
33. Høyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996; 93: 184-90
34. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995; 10: 263-71
35. Mattila M, Jääskeläinen J, Järvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995; 5: 441-6
36. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with depression. Int Clin Psychopharmacol 1995; 10: 3-9
37. Wheatley D, Kramer CME. A randomised, double-blind comparison of mirtazapine and fluoxeline in patients with major depression [abstract]. American Psychiatric Association Annual Meeting; 1997 May 17-22; San Diego, New Research Program and Abstracts: 124
38. Kasper S. Clinical efficacy of mirtazapine: a pooled-data analysis of four US studies [abstract]. 35th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 1996 Dec 8-13: San Juan, Puerto Rico: 107
39. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum Psychopharmacol 1995; 10 Suppl. 2: S135-45
40. Bruijn JA, Moleman P, Mulder PGH, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology 1996; 127: 231-7
41. Kasper S, Zivkov M, Roes KCB, et al. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997; 7: 115-24
42. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997; 17 Suppl. 1: 19-29
43. Akiskal H. Mood disorders: clinical features. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry VI. Baltimore (MD): Williams and Wilkins, 1995: 1123-52
44. Kasper S. Mirtazapine: a novel antidepressant combining clinical efficacy with improved tolerability. Primary Care Psychiatry 1997; 3: 7-16
45. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: results from a placebo-controlled trial. Drug Invest 1994; 8: 339-44
46. Bremner JD, Smith WT. Org 3770 vs amitriptyline in the continuation treatment of depression: a placebo controlled trial. Eur J Psychiatry 1996; 10: 5-15
47. Bech P, Allerup P, Reisby N, et al. Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants. Psychopharmacology 1984; 84: 276-81
48. Burrows GD, Kremer CME. Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol 1997; 17 Suppl. 1: 34-9
49. Stahl SM, Kremer CME, Pinder RM. Tolerability of mirtazapine used in high or low initial dose [abstract]. American Psychaitric Association Annual Meeting: 1997 May 17-22; San Diego, New Research Program and Abstracts: 133
50. Richelson E. The pharmacologic rationale behind antidepressant efficacy in severe depression. J Clin Psychiatry 1996; 57: 559-60
51. 3 receptors [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 4: 62
52. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994; 10: 18-46
53. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310: 221-4
54. de Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992; 43 Suppl. 2: 40-7
55. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53: 61-6
56. Doogan DP. Toleration and safety of sertraline: experience worldwide, Int Clin Psychopharmacol 1991; 6 Suppl. 2: 47-56
57. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46: 59-67
58. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13
59. Mann JJ, Kapur S. The emergence of suicidal ideation and behaviour during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991; 48: 1027-33
60. Kasper S, Schindler S, Neumeister A. Risk of suicide in depression and its implications for psychopharmacological treatment. Int Clin Psychopharmacol 1996; 11: 71-9
61. Clifford Lane H, Fauci AS. Sjögrens syndrome. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrisons principles of internal medicine. 12th ed. New York: McGraw-Hill Inc. Health Professions Division, 1991: 1449-50
62. Heimpel H. Drug-induced agranulocytosis. Med Toxicol 1988; 3: 449-62
63. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289-99
64. Hoes MJAJM, Zijpveld JHB. First report of mirtazapine overdose [letter]. Int Clin Psychopharmacol 1996; 11: 147
65. Zivkov M, Kremer CME, Hoes MJAJM, et al. Safety of mirtazapine in overdose [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 4: 62